Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Active
Last updated: January 13, 2026
Drospirenone-Only Emergency Contraceptive Pill
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Oral
  • Intended Duration: Emergency
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): University of Colorado, Denver
Inactive
Last updated: January 13, 2026
Emergency DMPA Injectable
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Emergency
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): University of Southern California
Inactive
Last updated: January 13, 2026
Umbrella Reversible Sterilization Device
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Fallopian Tube
  • Intended Duration: Permanent
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Third Xiangya Hospital of Central South University, Shanghai East Hospital of Tongji University
Active
Last updated: January 13, 2026
Tenofovir + Levonorgestrel Vaginal Film
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): University of Lagos
Active
Last updated: January 13, 2026
Propranolol Hydrochloride Mucoadhesive Invasomes

PNL-Loaded INVs-Gel

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Cairo University, Misr University for Science and Technology
Active
Last updated: January 13, 2026
CS/ODex/β-GP Injectable Hydrogel
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Not Yet Determined
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Northeast Forestry University, National Research Institute for Family Planning
Active
Last updated: January 13, 2026
Hydro-Ethanol Extract of Caesalpinia Pulcherrima
  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Not Yet Determined
  • Intended Duration: Not Yet Determined
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Vidyasagar University
Active
Last updated: January 13, 2026
Drug Eluting Embolization Particles
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Fallopian Tube
  • Intended Duration: Permanent
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): University of Washington, Oregon Health & Science University
Active
Last updated: January 13, 2026
pH-Responsive Copper IUD

Smart IUD

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Intrauterine
  • Intended Duration: Long-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): University of Pisa
Active
Last updated: January 13, 2026
CatSper-Based Contraceptive Vaccine
  • User: Female/Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Long-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Rensselaer Polytechnic Institute, Yale University